Secondary Marketplace / Trade Private Companies / Buy and Sell Enveda Biosciences Stock
Enveda Biosciences Enveda Biosciences Stock
$623.65MM
Series C Valuation, Nov 2024
Register To Buy and Sell Private Company Shares
For more details on private stock price information, financing and valuation for Enveda Biosciences, register or login.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Enveda Biosciences Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Enveda Biosciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
11/21/2024 Series C $136MM $xx.xx $623.65MM Baillie Gifford, Cresset Partners, Dimension Capital, Fpv, Henry R. Kravis, Kinnevik, Lingotto, Lux Capital, Premji Invest, The Nature Conservancy, True Ventures
Price per Share
$xx.xx
Shares Outstanding
25,784,925
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Baillie Gifford, Cresset Partners, Dimension Capital, Fpv, Henry R. Kravis, Kinnevik, Lingotto, Lux Capital, Premji Invest, The Nature Conservancy, True Ventures
06/14/2024 Series B+ $65.69MM $xx.xx $377.48MM Dimension, Fpv, Henry R. Kravis, Kinnevik, True Ventures, Wireframe
Price per Share
$xx.xx
Shares Outstanding
14,132,527
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Dimension, Fpv, Henry R. Kravis, Kinnevik, True Ventures, Wireframe
04/20/2023 Series B-1 $21MM $xx.xx $258.89MM Allen & Company, Amino Collective, Dimension, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
6,662,266
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Amino Collective, Dimension, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
04/20/2023 Series B $74.31MM $xx.xx $258.89MM Allen & Company, Amino Collective, Dimension, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
18,860,406
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Amino Collective, Dimension, Fpv, Hummingbird Ventures, Jazz Venture Partners, Level Ventures, Lux Capital, Possible Ventures, True Ventures, Two Sigma Ventures, Wireframe Ventures
06/22/2021 Series A $30.16MM $xx.xx $95.67MM Catalio Capital, Chris Gibson, Hummingbird Vc, Lifeforce Capital, Lux Capital, True Ventures, Two Sigma Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
10,755,620
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Catalio Capital, Chris Gibson, Hummingbird Vc, Lifeforce Capital, Lux Capital, True Ventures, Two Sigma Ventures, Village Global, Wireframe Ventures
12/27/2020 Series Seed-5 $150,042.94 $xx.xx $12.77MM Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
914,896
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020 Series Seed-4 $56,759.77 $xx.xx $12.77MM Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
291,824
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020 Series Seed-3 $225,023.89 $xx.xx $12.77MM Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
588,144
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020 Series Seed-2 $145,003.08 $xx.xx $12.77MM Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
326,878
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020 Series Seed-1 $304,331.88 $xx.xx $12.77MM Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
662,888
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
12/27/2020 Series Seed $4.1MM $xx.xx $12.77MM Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Price per Share
$xx.xx
Shares Outstanding
6,932,114
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chris Gibson, True Ventures, Village Global, Wireframe Ventures
Company Details
Enveda Biosciences is a drug discovery platform focusing on natural biological activity as a means of development. Their current pipeline includes pain and topical dermatology areas. Enveda Biosciences was founded in 2019 by Viswa Colluru Ph.D. and Pieter Dorrestein and is headquartered in Boulder, CO.
Founded
2019
Post-Money Valuation 3
$623.65MM
Total Funding
$332.14MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C
Enveda Biosciences Stock FAQs
To buy and sell Enveda Biosciences stock
Can you buy Enveda Biosciences stock?
As Enveda Biosciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Enveda Biosciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy Enveda Biosciences stock?

To invest in a private company like Enveda Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell Enveda Biosciences stock?
Yes, you may sell the Enveda Biosciences stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell Enveda Biosciences stock?

If you hold private company shares of Enveda Biosciences – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Enveda Biosciences on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
To learn more about Enveda Biosciences stock
Is Enveda Biosciences a public company?
No, Enveda Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is Enveda Biosciences’ stock price?
Enveda Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Enveda Biosciences private market stock price with Forge Data.
What is Enveda Biosciences’ stock ticker symbol?
Enveda Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Enveda Biosciences Investors Also Invested in These Private Companies

Henry R. Kravis
Dimension Capital
Amino Collective
Chris Gibson
Cresset Partners
Possible Ventures
Hummingbird Vc

Leadership & Board

Leadership

Viswa Colluru
Founder & Chief Executive Officer
August Allen
Chief Technology Officer
Dan Wee
Chief of Staff
Hannah Gordon
Chief Product Officer
Robert Buckley
Chief People Officer
Joe Rokicki
Founding Fellow
Sotirios Karanthanasis
Founding Fellow

Board

Harsh Patel
Wireframe Ventures
Shaquille Vayda
Lux Capital
Pegah Ebrahimi
FPV Ventures
Zavain Dar
Recursion Pharmaceuticals

Enveda Biosciences News and Media Highlights

Enveda Biosciences raises $130M to advance AI-driven drug discovery from natural compounds

Enveda Biosciences Inc., a biotechnology company that leverages artificial intelligence to develop new medicines, announced that it has raised $130 million in new funding.

Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials

In a series B funding round led by Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy Enveda raised $55 million.

Enveda’s Matured Platform Drives Toward Three INDs in 2023

Since its launch in 2019, Enveda Biosciences has raised $124 million to advance its pipeline of nature-based small molecules targeting difficult therapeutic problems, most recently closing a Series B round in the midst of a stingy financing environment.

Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer

Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the company’s Chief Medical Officer. Dr. Deeg is a medical and pharmaceutical leader with broad experience developing drugs and digital therapeutics at companies from biopharma startups to pharmaceutical giants like Eli Lilly & Co., where he spent more than a decade.
Browse Insights
Other Companies Like Enveda Biosciences in the Healthcare software Sector
Sector: Healthcare
Subsector: Healthcare software
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
AbridgeAbridge----$xx.xxSeries D$2.75B$xx.xx$250MM
Hippocratic AIHippocratic AI----$xx.xxSeries B$1.64B$xx.xx$141MM
InnovaccerInnovaccer$7.39+89.49%$xx.xxSeries F-1$3.88B$xx.xx$153.04MM
Insilico MedicineInsilico Medicine----$xx.xx--------
Maze TherapeuticsMaze Therapeutics----$xx.xxSeries D$551.86MM$xx.xx$73.3MM
Rad AIRad AI----$xx.xxSeries B-1$276.13MM$xx.xx$33.21MM
SukiSuki----$xx.xxSeries D$283.39MM$xx.xx$50MM
TraceLinkTraceLink----$xx.xxSeries D$657MM$xx.xx$60MM
VinetiVineti----$xx.xxSeries C$216.51MM$xx.xx$60MM
Viz.aiViz.ai----$xx.xxSeries D$1.28B$xx.xx$120MM

Updated on: Jan 17, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.